Revolution Medicines, Inc. (RVMDW) income statement

RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 3/30

$9.81+0.18 (+1.82%)

Close on Oct 30, 2026Market cap $41.00BP/E –Yield –

Revolution Medicines, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	0	0	12	35	29	43	50	20
Research & Development	987	592	423	253	187	132	92	51
General & Administrative	195	97	76	41	30	21	12	9.41
Operating Expenses	1,182	690	499	294	217	154	104	60
Operating Income	-1,182	-690	-487	-258	-188	-111	-54	-40
Interest Expense	24	0	0	0	0.01	0.07	0.11	0.12
Interest & Investment Income	91	87	47	9.15	0.93	2.24	2.19	0.78
Other Non-Operating Income	51	89	47	9.15	0.92	2.17	2.08	-1.46
Asset Impairment Charges	0	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	-0.03	-0.12	-0.05	-0.02	-0.12	0	-0.23	-0.20
Pretax Income	-1,131	-601	-440	-249	-187	-109	-52	-42
Income Tax Expense	0	-0.75	-3.52	-0.42	0	-0.37	-4.37	–
Net Income incl. Noncontrolling Interests	-1,131	-600	-436	-249	-187	-108	-48	-42
Net Income	-1,131	-600	-436	-249	-187	-108	-48	-42
Net Income to Common	-1,131	-600	-436	-249	-187	-110	-62	-49
EPS (Basic)(per share)	-5.95	-3.58	-3.86	-3.08	-2.57	-2.01	-22.33	-21.24
EPS (Diluted)(per share)	-5.95	-3.58	-3.86	-3.08	-2.57	-2.01	-22.33	-21.24
Shares Outstanding (Basic, Weighted)(shares)	190	168	113	81	73	55	2.77	2.30
Shares Outstanding (Diluted, Weighted)(shares)	190	168	113	81	73	55	2.77	2.30
EBITDA	-1,175	-683	-482	-254	-185	-108	-52	-39

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -58.1%

Financial strength

Current ratio: 11.38
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 230.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 15.73
Dividend yield: –